Abstract 1572: Dystrophin Is a tumor suppressor in human cancers with myogenic programs
Yuexiang Wang(Shanghai Institute of Nutrition and Health), Jonathan A. Fletcher(Harvard University), Louis M. Kunkel(Boston Children's Hospital), Mei‐Jun Zhu(Washington State University), Christopher Fletche(Brigham and Women's Hospital), Richard D. Bennett, Matt van de Rijn(Stanford University), George D. Demetri(Dana-Farber Cancer Institute), Grant Eilers(Brigham and Women's Hospital), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Chandrajit P. Raut(Dana-Farber Cancer Institute), Adrián Mariño‐Enríquez(Harvard University Press)
Cited by 4
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k